<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376790</url>
  </required_header>
  <id_info>
    <org_study_id>20130207</org_study_id>
    <secondary_id>2014-004869-24</secondary_id>
    <nct_id>NCT02376790</nct_id>
  </id_info>
  <brief_title>Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis</brief_title>
  <official_title>A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about the role of etanercept alone or in
      combination with methotrexate on disease activity in adults with psoriatic arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a 30-day screening period, a 48-week double-blind treatment period
      and a 30-day safety follow-up period.

      At or after week 24, participants with an inadequate response could receive rescue therapy
      with etanercept plus methotrexate until the end of the treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 3, 2015</start_date>
  <completion_date type="Actual">July 6, 2018</completion_date>
  <primary_completion_date type="Actual">January 9, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>A positive ACR20 response is defined if the following 3 criteria for improvement from baseline were met:
≥ 20% improvement in 68 tender joint count;
≥ 20% improvement in 66 swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Patient's assessment of joint pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
C-reactive protein concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Minimal Disease Activity (MDA) Response at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Minimal Disease Activity (MDA) is a measure of low disease activity specific for psoriatic arthritis (PsA) that incorporates measures of joint and entheseal inflammation, skin disease, patient reported outcomes and functional disability to assess disease activity. Participants were classified as achieving MDA if they fulfilled 5 of the following 7 outcome measures:
Tender joint count (0-68) ≤ 1
Swollen joint count (0-66) ≤ 1
Body surface area (BSA) involvement with psoriasis (0% to 100%) ≤ 3%
Patient global assessment of joint pain VAS (0-100) ≤ 15
Patient global assessment of disease activity VAS (0-100) ≤ 20
HAQ-DI (0-3) ≤ 0.5
Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index (18 sites assessed for enthesitis with an overall score of 0 - 16) ≤ 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response Over Time</measure>
    <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
    <description>A positive ACR20 response is defined if the following 3 criteria for improvement from baseline were met:
≥ 20% improvement in 68 tender joint count;
≥ 20% improvement in 66 swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Patient's assessment of joint pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
C-reactive protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response Over Time</measure>
    <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
    <description>A positive ACR50 response is defined if the following 3 criteria for improvement from baseline were met:
≥ 50% improvement in 68 tender joint count;
≥ 50% improvement in 66 swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of joint pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
C-reactive protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response Over Time</measure>
    <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
    <description>A positive ACR70 response is defined if the following 3 criteria for improvement from baseline were met:
≥ 70% improvement in 68 tender joint count;
≥ 70% improvement in 66 swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of joint pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
C-reactive protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tender Joint Count Over Time</measure>
    <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
    <description>The tender joint count is an assessment of the pain and/or tenderness of 68 joints using a 0 to 1 point scale (0 = none, 1 = present). The total tender joint count is calculated by summing the number of joints with present tenderness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Swollen Joint Count Over Time</measure>
    <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
    <description>The swollen joint count is an assessment of the swelling of 66 joints using a 0 to 1 point scale (0 = none, 1 = present). The total swollen joint count is calculated by summing the number of joints with present swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician Global Assessment of Disease Activity Over Time</measure>
    <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
    <description>A global assessment of the participant's arthritis assessed by the physician on a 100 mm visual analog scale (VAS) where 0 mm = No activity at all and 100 mm = Worst activity imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Assessment of Disease Activity Over Time</measure>
    <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
    <description>A global assessment of the participant's arthritis, assessed by the participant on a 100 mm VAS where 0 mm = No arthritis activity at all and 100 mm = Worst arthritis activity imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Assessment of Joint Pain Over Time</measure>
    <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
    <description>A global assessment of the severity of the participant's joint pain, assessed by the participant on a 100 mm VAS where 0 mm = No pain at all and 100 mm = Worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) Over Time</measure>
    <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
    <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-reactive Protein Concentration Over Time</measure>
    <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
    <description>C-reactive protein (CRP) is a specific measure of inflammatory activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a American Minimal Disease Activity (MDA) Response Over Time</measure>
    <time_frame>Weeks 4, 8, 12, 24, 36, and 48</time_frame>
    <description>Minimal Disease Activity (MDA) is a measure of low disease activity specific for psoriatic arthritis (PsA) that incorporates measures of joint and entheseal inflammation, skin disease, patient reported outcomes and functional disability to assess disease activity. Participants were classified as achieving MDA if they fulfilled 5 of the following 7 outcome measures:
Tender joint count (0-68) ≤ 1
Swollen joint count (0-66) ≤ 1
Body surface area (BSA) involvement with psoriasis (0% to 100%) ≤ 3%
Patient global assessment of joint pain VAS (0-100) ≤ 15
Patient global assessment of disease activity VAS (0-100) ≤ 20
HAQ-DI (0-3) ≤ 0.5
Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index (18 sites assessed for enthesitis with an overall score of 0 - 16) ≤ 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) Over Time</measure>
    <time_frame>Baseline and weeks 12, 24, 36, and 48</time_frame>
    <description>PASDAS is a measure of disease activity derived from the following variables:
Physician and patient global assessment of disease activity (assessed on a 0-100 VAS)
68 tender joint count
66 swollen joint count
Short Form-36 Questionnaire (SF-36) physical component summary (general health status on a scale from 0-100)
Tender dactylitis count (each digit assessed for tender dactylitis; total score 0-20)
Leeds enthesitis index (enthesitis assessed at 6 sites; total score of 0-6)
CRP level (mg/L)
The composite score is a weighted index where higher scores indicate more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Disease Activity Index (CDAI) Over Time</measure>
    <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
    <description>The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the following items:
28 tender joint count,
28 swollen joint count,
Patient's Global Assessment of Disease Activity measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest;
Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest.
The CDAI score ranges from 0-76 where lower scores indicate less disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Simplified Disease Activity Index (SDAI) Over Time</measure>
    <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
    <description>The Simplified Disease Activity Index (SDAI) is a composite index that is calculated as the sum of the following items:
28 tender joint count,
28 swollen joint count,
Patient's Global Assessment of Disease Activity measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest;
Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest.
CRP
The SDAI score ranges from 0 to 86 with higher scores representing worse disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Disease Activity Score 28 (DAS28) Over Time</measure>
    <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
    <description>The DAS28 measures the severity of disease at a specific time and is derived from the following variables:
28 tender joint count
28 swollen joint count
C-reactive protein (CRP)
Patient's global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest.
DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring in 8 functional areas: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Medical Outcomes Health Survey Short Form 36 Items Version 2 (SF-36 v2) at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains. Two summary component scores are calculated: mental component summary score (MCS) and physical component summary score (PCS). The MCS consists of social functioning, vitality, mental health, and role-emotional scales and the PCS consists of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The modified NAPSI scale is a grading system for nail psoriasis that incorporates the following 7 clinical features:
pitting (scores 0-3, depending on the number of pits)
nail plate crumbling (scores 0-3, depending on the % of nail involvement)
onycholysis and oil drop dyschromia (scores 0-3, depending on the % of nail involvement)
leukonychia (0 = absent, 1 = present)
red spots in lunula (0 = absent, 1 = present)
nail bed hyperkeratosis (0 = absent, 1 = present)
splinter hemorrhages (0 = absent, 1 = present)
In participants with fingernails involved with psoriasis, each fingernail was scored at baseline to determine the worst fingernail (ie, the fingernail with the highest mNAPSI score). This fingernail was followed for the remainder of the study.
mNAPSI scores range from 0-13 where higher scores represent worse nail disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clear mNAPSI at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The modified NAPSI scale is a grading system for nail psoriasis that incorporates the following 7 clinical features:
pitting (scores 0-3, depending on the number of pits)
nail plate crumbling (scores 0-3, depending on the % of nail involvement)
onycholysis and oil drop dyschromia (scores 0-3, depending on the % of nail involvement)
leukonychia (0 = absent, 1 = present)
red spots in lunula (0 = absent, 1 = present)
nail bed hyperkeratosis (0 = absent, 1 = present)
splinter hemorrhages (0 = absent, 1 = present)
In participants with fingernails involved with psoriasis, each fingernail was scored at baseline to determine the worst fingernail (ie, the fingernail with the highest mNAPSI score). This fingernail was followed for the remainder of the study.
mNAPSI scores range from 0-13 where higher scores represent worse nail disease. Clear mNAPSI is defined as a score = 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Leeds Dactylitis Index (LDI) at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The Leeds dactylitis index quantitatively measures dactylitis using the circumference of involved digits and control digits and tenderness of involved digits. Digits affected by dactylitis are defined as those with a 10% difference in the ratio of circumference of the affected digit to the contralateral digit. The control digit is either the contralateral digit (digit on opposite hand or foot), or if the contralateral digit is also affected, values from a standard reference table. Tenderness of affected digits is assessed on a scale from 0 [none] to 3 [worst]. The ratio of circumference between an affected digit and the control digit is multiplied by the tenderness score for the affected digit. The results from each involved digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clear LDI at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The Leeds dactylitis index quantitatively measures dactylitis using the circumference of involved digits and control digits and tenderness of involved digits. Digits affected by dactylitis are defined as those with a 10% difference in the ratio of circumference of the affected digit to the contralateral digit. The control digit is either the contralateral digit (digit on opposite hand or foot), or if the contralateral digit is also affected, values from a standard reference table. Tenderness of affected digits is assessed on a scale from 0 [none] to 3 [worst]. The ratio of circumference between an affected digit and the control digit is multiplied by the tenderness score for the affected digit. The results from each involved digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis.
Clear LDI is defined as a score = 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The SPARCC enthesitis index assesses enthesitis at 18 sites for palpitation with a resultant total score of 0 to 16 (for scoring purposes, the inferior patella and tibial tuberosity are considered 1 site because of their anatomical proximity). Tenderness at each site is quantified on a dichotomous basis (0 = non-tender, 1 = tender). Entheses assessed are medial epicondyle (left and right), lateral epicondyle (left and right), supraspinatus insertion into greater tuberosity of humerus (left and right), greater trochanter (left and right), quadriceps insertion into superior border of patella (left and right), patellar ligament insertion into inferior pole of patella or tibial tubercle (left and right), Achilles tendon insertion into calcaneum (left and right), plantar fascia insertion into calcaneum (left and right). A higher count represents greater enthesitis burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clear SPARCC Enthesitis Index Score at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The SPARCC enthesitis index assesses enthesitis at 18 sites for palpitation with a resultant total score of 0 to 16 (for scoring purposes, the inferior patella and tibial tuberosity are considered 1 site because of their anatomical proximity). Tenderness at each site is quantified on a dichotomous basis (0 = non-tender, 1 = tender). Entheses assessed are medial epicondyle (left and right), lateral epicondyle (left and right), supraspinatus insertion into greater tuberosity of humerus (left and right), greater trochanter (left and right), quadriceps insertion into superior border of patella (left and right), patellar ligament insertion into inferior pole of patella or tibial tubercle (left and right), Achilles tendon insertion into calcaneum (left and right), plantar fascia insertion into calcaneum (left and right). A higher count represents greater enthesitis burden.
Clear SPARCC enthesitis is defined as a score = 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Improvement From Baseline in the Percentage of Body Surface Area (BSA) Involved in Psoriasis at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The physician's assessment of the percentage of the participant's total body surface area involved with psoriasis.
Percent improvement from baseline = (Baseline Value - Post-baseline Value) / Baseline * 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Improvement From Baseline in the Percentage of Body Surface Area (BSA) Involved in Psoriasis by Baseline BSA Involvement Subgroups</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The physician's assessment of the percentage of the participant's total body surface area involved with psoriasis.
Percent improvement from baseline = (Baseline Value - Post-baseline Value) / Baseline * 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Physician Global Assessment (sPGA) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Physician Global Assessment (sPGA) at Week 24 by Baseline BSA Involvement Subgroups</measure>
    <time_frame>Week 24</time_frame>
    <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Static Physician Global Assessment (sPGA) Score at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Static Physician Global Assessment (sPGA) Score at Week 24 by Baseline BSA Involvement Subgroups</measure>
    <time_frame>Week 24</time_frame>
    <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an sPGA Score of 0 (Clear) or 1 (Almost Clear) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an sPGA Score of 0 (Clear) or 1 (Almost Clear) at Week 24 by Baseline BSA Involvement Subgroups</measure>
    <time_frame>Week 24</time_frame>
    <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least a 1 Grade Improvement in sPGA From Baseline at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least a 1 Grade Improvement in sPGA From Baseline at Week 24 by Baseline BSA Involvement Subgroups</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least a 2 Grade Improvement in sPGA From Baseline at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least a 2 Grade Improvement in sPGA From Baseline at Week 24 by Baseline BSA Involvement Subgroups</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">851</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Methotrexate Monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate + Etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received etanercept 50 mg a week by subcutaneous injection plus oral methotrexate 20 mg weekly for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Etanercept was administered by subcutaneous injection once a week</description>
    <arm_group_label>Etanercept Monotherapy</arm_group_label>
    <arm_group_label>Methotrexate + Etanercept</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate capsules taken orally once a week. Dosing was initiated at 10 mg weekly and titrated up to a final dose of 20 mg weekly over a 4-week period.</description>
    <arm_group_label>Methotrexate + Etanercept</arm_group_label>
    <arm_group_label>Methotrexate Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Etanercept</intervention_name>
    <description>Placebo to etanercept was administered by subcutaneous injection once a week.</description>
    <arm_group_label>Methotrexate Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Methotrexate</intervention_name>
    <description>Placebo to methotrexate capsules taken orally once a week.</description>
    <arm_group_label>Etanercept Monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Subject must have a diagnosis of psoriatic arthritis (PsA) by the Classification
             Criteria for Psoriatic Arthritis (CASPAR) criteria.

          -  Subject has ≥ 3 tender and ≥ 3 swollen joints at screening and at baseline.

          -  Subject has an active psoriatic skin lesion

          -  Subject is naïve to etanercept and any other biologic for the treatment for PsA or
             psoriasis.

          -  Subject has no prior use of methotrexate for PsA.

          -  Subject has no history of tuberculosis

          -  Subject has a negative test for tuberculosis, hepatitis B and C.

        Exclusion Criteria:

          -  Subject has known history of alcoholic hepatitis, nonalcoholic steatohepatitis or
             immunodeficiency syndromes, including human immunodeficiency virus (HIV) infection.

          -  Subject has any active infection (including chronic or localized infections) for which
             anti-infectives were indicated within 4 weeks prior to the first dose of
             investigational product.

          -  Subject has a serious infection, defined as requiring hospitalization or intravenous
             anti-infectives within 8 weeks prior to the first dose of investigational product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mather</city>
        <state>California</state>
        <zip>95655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48917</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clifton</city>
        <state>New Jersey</state>
        <zip>07012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rouse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3N 0K6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3H7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 3H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 3M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>7501126</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>7640881</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>638 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava-Trebovice</city>
        <zip>722 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 50</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon Cédex 3</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liepaja</city>
        <zip>3401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>1003</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valmiera</city>
        <zip>4201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexicali</city>
        <state>Baja California Norte</state>
        <zip>21100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexicalli</city>
        <state>Baja California Norte</state>
        <zip>21200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45190</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64718</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Culiacan</city>
        <state>Sinaloa</state>
        <zip>80000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-436</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-817</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-318</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1050-034</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-034</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ponte de Lima</city>
        <zip>4990-041</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kursk</city>
        <zip>305007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orenburg</city>
        <zip>460018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vladimir</city>
        <zip>600023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Panorama</city>
        <state>Western Cape</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pinelands</city>
        <state>Western Cape</state>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stellenbosch</city>
        <state>Western Cape</state>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <state>Andalucía</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Vila-Joiosa</city>
        <state>Comunidad Valenciana</state>
        <zip>03570</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Merida</city>
        <state>Extremadura</state>
        <zip>06800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruña</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bradford</city>
        <zip>BD5 0NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dudley</city>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Mease PJ, Gladman DD, Samad AS, Coates LC, Liu LXH, Aras GA, Collier DH, Chung JB. Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA). RMD Open. 2018 Feb 3;4(1):e000606. doi: 10.1136/rmdopen-2017-000606. eCollection 2018.</citation>
    <PMID>29531787</PMID>
  </reference>
  <reference>
    <citation>Philip Mease, M.D.,1* Dafna Gladman, M.D.,2 David H Collier, M.D.,3 Christopher T. Ritchlin, M.D., M.P.H.,4 Philip Helliwell, M.D.,5 Lyrica Liu, Ph.D.,3 Greg Kricorian, M.D.,3 James B. Chung, M.D., Ph.D.3. Etanercept and Methotrexate as Monotherapy or in Combination to Treat Patients With Psoriatic Arthritis. Arthritis Rheumatol.</citation>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 28, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <results_first_submitted>January 8, 2019</results_first_submitted>
  <results_first_submitted_qc>February 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 22, 2019</results_first_posted>
  <last_update_submitted>March 4, 2019</last_update_submitted>
  <last_update_submitted_qc>March 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriatic Arthritis</keyword>
  <keyword>Arthritis, Psoriasis</keyword>
  <keyword>Etanercept</keyword>
  <keyword>Enbrel</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Minimal Disease Activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 31, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02376790/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02376790/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 124 centers in Europe, Latin America, North America, and South Africa. Participants were enrolled from 03 March 2015 to 07 July 2017.</recruitment_details>
      <pre_assignment_details>The study consisted of a 30-day screening period, a 48-week randomized double blind treatment period, and a 30-day safety follow-up period.
Participants were randomly assigned in a 1:1:1 ratio to 1 of 3 treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Methotrexate Monotherapy</title>
          <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Etanercept Monotherapy</title>
          <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Etanercept + Methotrexate</title>
          <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="284"/>
                <participants group_id="P2" count="284"/>
                <participants group_id="P3" count="283"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="282"/>
                <participants group_id="P2" count="284"/>
                <participants group_id="P3" count="282"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
                <participants group_id="P2" count="237"/>
                <participants group_id="P3" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="53"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Decision by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Methotrexate Monotherapy</title>
          <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Etanercept Monotherapy</title>
          <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Etanercept + Methotrexate</title>
          <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="284"/>
            <count group_id="B2" value="284"/>
            <count group_id="B3" value="283"/>
            <count group_id="B4" value="851"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="284"/>
                    <count group_id="B2" value="284"/>
                    <count group_id="B3" value="283"/>
                    <count group_id="B4" value="851"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.7" spread="13.1"/>
                    <measurement group_id="B2" value="48.5" spread="13.5"/>
                    <measurement group_id="B3" value="48.1" spread="12.7"/>
                    <measurement group_id="B4" value="48.4" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="284"/>
                    <count group_id="B2" value="284"/>
                    <count group_id="B3" value="283"/>
                    <count group_id="B4" value="851"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>≤ 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="257"/>
                    <measurement group_id="B2" value="251"/>
                    <measurement group_id="B3" value="259"/>
                    <measurement group_id="B4" value="767"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="284"/>
                    <count group_id="B2" value="284"/>
                    <count group_id="B3" value="283"/>
                    <count group_id="B4" value="851"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="139"/>
                    <measurement group_id="B4" value="432"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="144"/>
                    <measurement group_id="B4" value="419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="284"/>
                    <count group_id="B2" value="284"/>
                    <count group_id="B3" value="283"/>
                    <count group_id="B4" value="851"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="197"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="214"/>
                    <measurement group_id="B3" value="214"/>
                    <measurement group_id="B4" value="654"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="284"/>
                    <count group_id="B2" value="284"/>
                    <count group_id="B3" value="283"/>
                    <count group_id="B4" value="851"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black (or African American)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed Race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="255"/>
                    <measurement group_id="B2" value="252"/>
                    <measurement group_id="B3" value="265"/>
                    <measurement group_id="B4" value="772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <population>Participants with available data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="284"/>
                    <count group_id="B2" value="283"/>
                    <count group_id="B3" value="283"/>
                    <count group_id="B4" value="850"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>≤ 30 kg/m²</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="160"/>
                    <measurement group_id="B4" value="459"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 30 kg/m²</title>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Use of Non-biologic Disease Modifying Antirheumatic Drugs (DMARDs)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="284"/>
                    <count group_id="B2" value="284"/>
                    <count group_id="B3" value="283"/>
                    <count group_id="B4" value="851"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="246"/>
                    <measurement group_id="B2" value="258"/>
                    <measurement group_id="B3" value="240"/>
                    <measurement group_id="B4" value="744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Psoriatic Arthritis Disease</title>
          <population>Participants with available data</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="231"/>
                    <count group_id="B2" value="222"/>
                    <count group_id="B3" value="231"/>
                    <count group_id="B4" value="684"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.64" spread="6.85"/>
                    <measurement group_id="B2" value="3.10" spread="5.96"/>
                    <measurement group_id="B3" value="2.96" spread="5.99"/>
                    <measurement group_id="B4" value="3.24" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swollen Joint Count</title>
          <description>A total of 66 joints were scored for presence or absence of swelling.</description>
          <population>Participants with available data</population>
          <units>joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="284"/>
                    <count group_id="B2" value="283"/>
                    <count group_id="B3" value="282"/>
                    <count group_id="B4" value="849"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.9" spread="9.9"/>
                    <measurement group_id="B2" value="11.5" spread="9.6"/>
                    <measurement group_id="B3" value="11.2" spread="9.1"/>
                    <measurement group_id="B4" value="11.9" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tender Joint Count</title>
          <description>A total of 68 joints were scored for presence or absence of tenderness.</description>
          <population>Participants with available data</population>
          <units>joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="284"/>
                    <count group_id="B2" value="283"/>
                    <count group_id="B3" value="282"/>
                    <count group_id="B4" value="849"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.9" spread="15.0"/>
                    <measurement group_id="B2" value="18.8" spread="14.5"/>
                    <measurement group_id="B3" value="20.0" spread="15.3"/>
                    <measurement group_id="B4" value="19.9" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician Global Assessment of Disease Activity</title>
          <description>Assessed by the physician on a 100 mm visual analog scale (VAS), where 0 mm = No activity at all and 100 mm = Worst activity imaginable.</description>
          <population>Participants with available data</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="284"/>
                    <count group_id="B2" value="284"/>
                    <count group_id="B3" value="282"/>
                    <count group_id="B4" value="850"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="19.4"/>
                    <measurement group_id="B2" value="58.3" spread="18.2"/>
                    <measurement group_id="B3" value="58.0" spread="17.8"/>
                    <measurement group_id="B4" value="58.3" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Global Assessment of Disease Activity</title>
          <description>Assessed by the participant on a 100 mm VAS, where 0 mm = No arthritis activity at all and 100 mm = Worst arthritis activity imaginable.</description>
          <population>Participants with available data</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="283"/>
                    <count group_id="B2" value="284"/>
                    <count group_id="B3" value="282"/>
                    <count group_id="B4" value="849"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.7" spread="22.5"/>
                    <measurement group_id="B2" value="62.9" spread="22.1"/>
                    <measurement group_id="B3" value="61.0" spread="20.8"/>
                    <measurement group_id="B4" value="61.5" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Global Assessment of Joint Pain</title>
          <description>Participants assessed their joint pain on a 100 mm VAS, where 0 mm = No pain at all and 100 mm = Worst pain imaginable.</description>
          <population>Participants with available data</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="283"/>
                    <count group_id="B2" value="284"/>
                    <count group_id="B3" value="282"/>
                    <count group_id="B4" value="849"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" spread="21.7"/>
                    <measurement group_id="B2" value="56.5" spread="22.3"/>
                    <measurement group_id="B3" value="55.7" spread="21.6"/>
                    <measurement group_id="B4" value="56.1" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disability Index of the Health Assessment Questionnaire (HAQ-DI)</title>
          <description>The HAQ-DI is a patient-reported questionnaire consisting of 20 questions in eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability.</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="283"/>
                    <count group_id="B2" value="284"/>
                    <count group_id="B3" value="282"/>
                    <count group_id="B4" value="849"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" spread="0.6"/>
                    <measurement group_id="B2" value="1.1" spread="0.6"/>
                    <measurement group_id="B3" value="1.2" spread="0.6"/>
                    <measurement group_id="B4" value="1.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-reactive Protein (CRP) Concentration</title>
          <description>C-reactive protein (CRP) is a protein found in blood. CRP levels rise in response to inflammation.</description>
          <population>Participants with available data</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="284"/>
                    <count group_id="B2" value="282"/>
                    <count group_id="B3" value="283"/>
                    <count group_id="B4" value="849"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.52" spread="16.29"/>
                    <measurement group_id="B2" value="10.72" spread="15.59"/>
                    <measurement group_id="B3" value="8.70" spread="11.65"/>
                    <measurement group_id="B4" value="9.98" spread="14.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Psoriatic Arthritis Disease Activity Score (PASDAS)</title>
          <description>PASDAS is a measure of disease activity derived from the following:
Physician and patient global assessment of disease activity (0-100 VAS)
68 tender joint count
66 swollen joint count
Short Form-36 Questionnaire (SF-36) physical component summary (general health status on a scale from 0-100)
Tender dactylitis count (each digit assessed for tender dactylitis; total score 0-20)
Leeds enthesitis index (enthesitis assessed at 6 sites; total score of 0-6)
CRP
The composite score is a weighted index where higher scores indicate more severe disease.</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="282"/>
                    <count group_id="B2" value="279"/>
                    <count group_id="B3" value="280"/>
                    <count group_id="B4" value="841"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.10" lower_limit="2.2" upper_limit="9.1"/>
                    <measurement group_id="B2" value="6.02" lower_limit="2.5" upper_limit="10.2"/>
                    <measurement group_id="B3" value="5.95" lower_limit="3.0" upper_limit="9.4"/>
                    <measurement group_id="B4" value="6.02" lower_limit="2.2" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Disease Activity Index (CDAI)</title>
          <description>The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the following items:
28 tender joint count,
28 swollen joint count,
Patient's Global Assessment of Disease Activity measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest;
Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest.
The CDAI score ranges from 0-76 where lower scores indicate less disease activity.</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="283"/>
                    <count group_id="B2" value="283"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="847"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.51" spread="13.26"/>
                    <measurement group_id="B2" value="28.45" spread="12.89"/>
                    <measurement group_id="B3" value="28.55" spread="12.71"/>
                    <measurement group_id="B4" value="29.17" spread="12.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Simplified Disease Activity Index (SDAI)</title>
          <description>The Simplified Disease Activity Index (SDAI) is a composite index that is calculated as the sum of the following items:
28 tender joint count,
28 swollen joint count,
Patient's Global Assessment of Disease Activity measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest;
Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest.
CRP
The SDAI score ranges from 0 to 86 with higher scores representing worse disease.</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="283"/>
                    <count group_id="B2" value="281"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="845"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.56" spread="13.52"/>
                    <measurement group_id="B2" value="29.52" spread="13.19"/>
                    <measurement group_id="B3" value="29.43" spread="12.90"/>
                    <measurement group_id="B4" value="30.17" spread="13.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Activity Score 28 (DAS28)</title>
          <description>The DAS28 measures the severity of disease at a specific time and is derived from the following variables:
28 tender joint count
28 swollen joint count
C-reactive protein (CRP) concentration
Patient's global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest.
DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. Higher scores indicate higher disease activity.</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="283"/>
                    <count group_id="B2" value="281"/>
                    <count group_id="B3" value="281"/>
                    <count group_id="B4" value="845"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.93" spread="1.11"/>
                    <measurement group_id="B2" value="4.80" spread="1.13"/>
                    <measurement group_id="B3" value="4.75" spread="1.12"/>
                    <measurement group_id="B4" value="4.83" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical Outcomes Health Survey Short Form 36 Items Version 2 (SF-36 v2)</title>
          <description>The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains. Two summary component scores are calculated: mental component summary score (MCS) and physical component summary score (PCS). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning.</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>PCS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="282"/>
                    <count group_id="B2" value="284"/>
                    <count group_id="B3" value="282"/>
                    <count group_id="B4" value="848"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.587" spread="8.411"/>
                    <measurement group_id="B2" value="37.835" spread="8.381"/>
                    <measurement group_id="B3" value="37.353" spread="9.243"/>
                    <measurement group_id="B4" value="36.927" spread="8.730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="282"/>
                    <count group_id="B2" value="284"/>
                    <count group_id="B3" value="282"/>
                    <count group_id="B4" value="848"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.174" spread="12.073"/>
                    <measurement group_id="B2" value="45.107" spread="12.496"/>
                    <measurement group_id="B3" value="46.256" spread="11.236"/>
                    <measurement group_id="B4" value="45.511" spread="11.946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Leeds Dactylitis Index (LDI)</title>
          <description>The Leeds Dactylitis Index quantitatively measures dactylitis using the circumference of involved digits and control digits and tenderness of involved digits (on a scale from 0-3). The control digit is either the contralateral digit (digit on opposite hand or foot), or if the contralateral digit is also affected, from a standard reference table. The ratio of circumference between an affected digit and the control digit is multiplied by the tenderness score for the affected digit. The results from each involved digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis.</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="284"/>
                    <count group_id="B2" value="283"/>
                    <count group_id="B3" value="282"/>
                    <count group_id="B4" value="849"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.89" spread="174.56"/>
                    <measurement group_id="B2" value="50.07" spread="137.20"/>
                    <measurement group_id="B3" value="44.11" spread="143.17"/>
                    <measurement group_id="B4" value="50.37" spread="152.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index</title>
          <description>The SPARCC enthesitis index assesses enthesitis at 18 sites for palpitation with a resultant total score of 0 to 16 (for scoring purposes, the inferior patella and tibial tuberosity are considered 1 site because of their anatomical proximity). Tenderness at each site is quantified on a dichotomous basis (0 = non-tender, 1 = tender). A higher count represents greater enthesitis burden.</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="284"/>
                    <count group_id="B2" value="283"/>
                    <count group_id="B3" value="282"/>
                    <count group_id="B4" value="849"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.9" spread="4.3"/>
                    <measurement group_id="B2" value="3.7" spread="4.3"/>
                    <measurement group_id="B3" value="4.1" spread="4.5"/>
                    <measurement group_id="B4" value="3.9" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of Body Surface Area (BSA) Involved in Psoriasis</title>
          <description>The physician’s assessment of the percentage of the participant’s total body surface area involved with psoriasis.</description>
          <population>Participants with available data</population>
          <units>percent body surface area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="284"/>
                    <count group_id="B2" value="284"/>
                    <count group_id="B3" value="283"/>
                    <count group_id="B4" value="851"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.68" spread="18.78"/>
                    <measurement group_id="B2" value="10.76" spread="14.66"/>
                    <measurement group_id="B3" value="10.74" spread="15.58"/>
                    <measurement group_id="B4" value="11.40" spread="16.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Static Physician Global Assessment (sPGA)</title>
          <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician’s global assessment of the participant’s psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear
= mild
= moderate
= marked
= severe</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="281"/>
                    <count group_id="B2" value="284"/>
                    <count group_id="B3" value="283"/>
                    <count group_id="B4" value="848"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.6" spread="1.1"/>
                    <measurement group_id="B2" value="2.6" spread="1.0"/>
                    <measurement group_id="B3" value="2.5" spread="1.0"/>
                    <measurement group_id="B4" value="2.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24</title>
        <description>A positive ACR20 response is defined if the following 3 criteria for improvement from baseline were met:
≥ 20% improvement in 68 tender joint count;
≥ 20% improvement in 66 swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Patient's assessment of joint pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
C-reactive protein concentration.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>All randomized participants; missing postbaseline data were imputed using non-responder imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24</title>
          <description>A positive ACR20 response is defined if the following 3 criteria for improvement from baseline were met:
≥ 20% improvement in 68 tender joint count;
≥ 20% improvement in 66 swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Patient's assessment of joint pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
C-reactive protein concentration.</description>
          <population>All randomized participants; missing postbaseline data were imputed using non-responder imputation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.7"/>
                    <measurement group_id="O2" value="60.9"/>
                    <measurement group_id="O3" value="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary hypothesis of this study is that etanercept plus methotrexate therapy and etanercept monotherapy are more efficacious than methotrexate monotherapy as measured by the percentage of participants with psoriatic arthritis achieving ACR 20 response at week 24.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>Adjusted p-value was obtained by applying a Bonferroni-based testing procedure for multiplicity adjustment to control the family-wise, two-sided type one error rate at 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test with baseline body mass index (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD treatment as stratification factors</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>13.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.8</ci_lower_limit>
            <ci_upper_limit>22.0</ci_upper_limit>
            <estimate_desc>The risk difference was estimated using the Mantel-Haenszel estimate of common risk difference using the stratification factors described above.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary hypothesis of this study is that etanercept plus methotrexate therapy and etanercept monotherapy are more efficacious than methotrexate monotherapy as measured by the percentage of participants with psoriatic arthritis achieving ACR 20 response at week 24.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>Adjusted p-value was obtained by applying a Bonferroni-based testing procedure for multiplicity adjustment to control the family-wise, two-sided type one error rate at 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test with baseline body mass index (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD treatment as stratification factors</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>9.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>17.3</ci_upper_limit>
            <estimate_desc>The risk difference was estimated using the Mantel-Haenszel estimate of common risk difference using the stratification factors described above.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Minimal Disease Activity (MDA) Response at Week 24</title>
        <description>Minimal Disease Activity (MDA) is a measure of low disease activity specific for psoriatic arthritis (PsA) that incorporates measures of joint and entheseal inflammation, skin disease, patient reported outcomes and functional disability to assess disease activity. Participants were classified as achieving MDA if they fulfilled 5 of the following 7 outcome measures:
Tender joint count (0-68) ≤ 1
Swollen joint count (0-66) ≤ 1
Body surface area (BSA) involvement with psoriasis (0% to 100%) ≤ 3%
Patient global assessment of joint pain VAS (0-100) ≤ 15
Patient global assessment of disease activity VAS (0-100) ≤ 20
HAQ-DI (0-3) ≤ 0.5
Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index (18 sites assessed for enthesitis with an overall score of 0 - 16) ≤ 1</description>
        <time_frame>Week 24</time_frame>
        <population>All randomized participants; missing postbaseline data were imputed using non-responder imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Minimal Disease Activity (MDA) Response at Week 24</title>
          <description>Minimal Disease Activity (MDA) is a measure of low disease activity specific for psoriatic arthritis (PsA) that incorporates measures of joint and entheseal inflammation, skin disease, patient reported outcomes and functional disability to assess disease activity. Participants were classified as achieving MDA if they fulfilled 5 of the following 7 outcome measures:
Tender joint count (0-68) ≤ 1
Swollen joint count (0-66) ≤ 1
Body surface area (BSA) involvement with psoriasis (0% to 100%) ≤ 3%
Patient global assessment of joint pain VAS (0-100) ≤ 15
Patient global assessment of disease activity VAS (0-100) ≤ 20
HAQ-DI (0-3) ≤ 0.5
Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index (18 sites assessed for enthesitis with an overall score of 0 - 16) ≤ 1</description>
          <population>All randomized participants; missing postbaseline data were imputed using non-responder imputation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9"/>
                    <measurement group_id="O2" value="35.9"/>
                    <measurement group_id="O3" value="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The secondary hypothesis of this study was that etanercept plus methotrexate therapy and etanercept monotherapy are more efficacious than methotrexate monotherapy as measured by the percentage of participants with PsA achieving MDA response at week 24.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>Adjusted p-value was obtained by applying a Bonferroni-based testing procedure for multiplicity adjustment to control the family-wise, two-sided type one error rate at 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test with baseline body mass index (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD treatment as stratification factors</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>12.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.9</ci_lower_limit>
            <ci_upper_limit>19.6</ci_upper_limit>
            <estimate_desc>The risk difference was estimated using the Mantel-Haenszel estimate of common risk difference using the stratification factors described above.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The secondary hypothesis of this study was that etanercept plus methotrexate therapy and etanercept monotherapy are more efficacious than methotrexate monotherapy as measured by the percentage of participants with PsA achieving MDA response at week 24.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>Adjusted p-value was obtained by applying a Bonferroni-based testing procedure for multiplicity adjustment to control the family-wise, two-sided type one error rate at 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test with baseline body mass index (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD treatment as stratification factors</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>11.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.2</ci_lower_limit>
            <ci_upper_limit>18.9</ci_upper_limit>
            <estimate_desc>The risk difference was estimated using the Mantel-Haenszel estimate of common risk difference using the stratification factors described above.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response Over Time</title>
        <description>A positive ACR20 response is defined if the following 3 criteria for improvement from baseline were met:
≥ 20% improvement in 68 tender joint count;
≥ 20% improvement in 66 swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Patient's assessment of joint pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
C-reactive protein.</description>
        <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
        <population>All randomized participants with non-missing data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response Over Time</title>
          <description>A positive ACR20 response is defined if the following 3 criteria for improvement from baseline were met:
≥ 20% improvement in 68 tender joint count;
≥ 20% improvement in 66 swollen joint count; and
≥ 20% improvement in at least 3 of the 5 following parameters:
Patient's assessment of joint pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
C-reactive protein.</description>
          <population>All randomized participants with non-missing data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="280"/>
                    <count group_id="O2" value="280"/>
                    <count group_id="O3" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="44.3"/>
                    <measurement group_id="O3" value="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="271"/>
                    <count group_id="O2" value="274"/>
                    <count group_id="O3" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5"/>
                    <measurement group_id="O2" value="60.2"/>
                    <measurement group_id="O3" value="60.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.8"/>
                    <measurement group_id="O2" value="65.5"/>
                    <measurement group_id="O3" value="70.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="256"/>
                    <count group_id="O3" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5"/>
                    <measurement group_id="O2" value="69.5"/>
                    <measurement group_id="O3" value="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="256"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9"/>
                    <measurement group_id="O2" value="67.6"/>
                    <measurement group_id="O3" value="71.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="248"/>
                    <count group_id="O3" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3"/>
                    <measurement group_id="O2" value="77.0"/>
                    <measurement group_id="O3" value="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="237"/>
                    <count group_id="O3" value="230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7"/>
                    <measurement group_id="O2" value="83.1"/>
                    <measurement group_id="O3" value="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response Over Time</title>
        <description>A positive ACR50 response is defined if the following 3 criteria for improvement from baseline were met:
≥ 50% improvement in 68 tender joint count;
≥ 50% improvement in 66 swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of joint pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
C-reactive protein.</description>
        <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
        <population>All randomized participants with non-missing data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response Over Time</title>
          <description>A positive ACR50 response is defined if the following 3 criteria for improvement from baseline were met:
≥ 50% improvement in 68 tender joint count;
≥ 50% improvement in 66 swollen joint count; and
≥ 50% improvement in at least 3 of the 5 following parameters:
Patient's assessment of joint pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
C-reactive protein.</description>
          <population>All randomized participants with non-missing data at each time point</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                    <count group_id="O2" value="279"/>
                    <count group_id="O3" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="16.5"/>
                    <measurement group_id="O3" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="272"/>
                    <count group_id="O2" value="275"/>
                    <count group_id="O3" value="269"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1"/>
                    <measurement group_id="O2" value="31.3"/>
                    <measurement group_id="O3" value="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9"/>
                    <measurement group_id="O2" value="40.4"/>
                    <measurement group_id="O3" value="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="256"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2"/>
                    <measurement group_id="O2" value="43.8"/>
                    <measurement group_id="O3" value="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="257"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6"/>
                    <measurement group_id="O2" value="44.4"/>
                    <measurement group_id="O3" value="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="241"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.8"/>
                    <measurement group_id="O2" value="57.3"/>
                    <measurement group_id="O3" value="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="238"/>
                    <count group_id="O3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3"/>
                    <measurement group_id="O2" value="63.0"/>
                    <measurement group_id="O3" value="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of the percentage of participants with an ACR50 response at week 24.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test with baseline body mass index (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD treatment as stratification factors</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>14.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.4</ci_lower_limit>
            <ci_upper_limit>23.0</ci_upper_limit>
            <estimate_desc>The risk difference was estimated using the Mantel-Haenszel estimate of common risk difference using the stratification factors described above.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of the percentage of participants with an ACR50 response at week 24.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test with baseline body mass index (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD treatment as stratification factors</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>11.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.4</ci_lower_limit>
            <ci_upper_limit>20.2</ci_upper_limit>
            <estimate_desc>The risk difference was estimated using the Mantel-Haenszel estimate of common risk difference using the stratification factors described above.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response Over Time</title>
        <description>A positive ACR70 response is defined if the following 3 criteria for improvement from baseline were met:
≥ 70% improvement in 68 tender joint count;
≥ 70% improvement in 66 swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of joint pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
C-reactive protein.</description>
        <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
        <population>All randomized participants with non-missing data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response Over Time</title>
          <description>A positive ACR70 response is defined if the following 3 criteria for improvement from baseline were met:
≥ 70% improvement in 68 tender joint count;
≥ 70% improvement in 66 swollen joint count; and
≥ 70% improvement in at least 3 of the 5 following parameters:
Patient's assessment of joint pain (measured on a 100 mm visual analog scale [VAS]);
Patient's global assessment of disease activity (measured on a 100 mm VAS);
Physician's global assessment of disease activity (measured on a 100 mm VAS);
Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
C-reactive protein.</description>
          <population>All randomized participants with non-missing data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                    <count group_id="O2" value="280"/>
                    <count group_id="O3" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="272"/>
                    <count group_id="O2" value="277"/>
                    <count group_id="O3" value="269"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="15.2"/>
                    <measurement group_id="O3" value="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                    <count group_id="O2" value="268"/>
                    <count group_id="O3" value="264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                    <measurement group_id="O2" value="24.3"/>
                    <measurement group_id="O3" value="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="256"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7"/>
                    <measurement group_id="O2" value="24.2"/>
                    <measurement group_id="O3" value="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="257"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8"/>
                    <measurement group_id="O2" value="29.2"/>
                    <measurement group_id="O3" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="245"/>
                    <count group_id="O2" value="247"/>
                    <count group_id="O3" value="242"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6"/>
                    <measurement group_id="O2" value="38.5"/>
                    <measurement group_id="O3" value="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="237"/>
                    <count group_id="O3" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2"/>
                    <measurement group_id="O2" value="39.7"/>
                    <measurement group_id="O3" value="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of the percentage of participants with an ACR70 response at week 24.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test with baseline body mass index (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD treatment as stratification factors</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>13.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.5</ci_lower_limit>
            <ci_upper_limit>20.4</ci_upper_limit>
            <estimate_desc>The risk difference was estimated using the Mantel-Haenszel estimate of common risk difference using the stratification factors described above.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of the percentage of participants with an ACR70 response at week 24.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test with baseline body mass index (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD treatment as stratification factors</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>13.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.7</ci_lower_limit>
            <ci_upper_limit>20.7</ci_upper_limit>
            <estimate_desc>The risk difference was estimated using the Mantel-Haenszel estimate of common risk difference using the stratification factors described above.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tender Joint Count Over Time</title>
        <description>The tender joint count is an assessment of the pain and/or tenderness of 68 joints using a 0 to 1 point scale (0 = none, 1 = present). The total tender joint count is calculated by summing the number of joints with present tenderness.</description>
        <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
        <population>All randomized participants with non-missing data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tender Joint Count Over Time</title>
          <description>The tender joint count is an assessment of the pain and/or tenderness of 68 joints using a 0 to 1 point scale (0 = none, 1 = present). The total tender joint count is calculated by summing the number of joints with present tenderness.</description>
          <population>All randomized participants with non-missing data at each time point</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="280"/>
                    <count group_id="O2" value="279"/>
                    <count group_id="O3" value="277"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="0.6"/>
                    <measurement group_id="O2" value="-6.4" spread="0.6"/>
                    <measurement group_id="O3" value="-7.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="271"/>
                    <count group_id="O2" value="276"/>
                    <count group_id="O3" value="269"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="0.7"/>
                    <measurement group_id="O2" value="-8.9" spread="0.6"/>
                    <measurement group_id="O3" value="-9.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="0.7"/>
                    <measurement group_id="O2" value="-9.8" spread="0.7"/>
                    <measurement group_id="O3" value="-10.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="257"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="0.7"/>
                    <measurement group_id="O2" value="-10.9" spread="0.7"/>
                    <measurement group_id="O3" value="-11.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="257"/>
                    <count group_id="O3" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" spread="0.8"/>
                    <measurement group_id="O2" value="-10.9" spread="0.8"/>
                    <measurement group_id="O3" value="-11.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="245"/>
                    <count group_id="O2" value="248"/>
                    <count group_id="O3" value="243"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.5" spread="0.8"/>
                    <measurement group_id="O2" value="-12.7" spread="0.8"/>
                    <measurement group_id="O3" value="-12.9" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="239"/>
                    <count group_id="O3" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.5" spread="0.8"/>
                    <measurement group_id="O2" value="-13.9" spread="0.8"/>
                    <measurement group_id="O3" value="-12.9" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Swollen Joint Count Over Time</title>
        <description>The swollen joint count is an assessment of the swelling of 66 joints using a 0 to 1 point scale (0 = none, 1 = present). The total swollen joint count is calculated by summing the number of joints with present swelling.</description>
        <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
        <population>All randomized participants with non-missing data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Swollen Joint Count Over Time</title>
          <description>The swollen joint count is an assessment of the swelling of 66 joints using a 0 to 1 point scale (0 = none, 1 = present). The total swollen joint count is calculated by summing the number of joints with present swelling.</description>
          <population>All randomized participants with non-missing data at each time point</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="280"/>
                    <count group_id="O2" value="279"/>
                    <count group_id="O3" value="277"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="0.4"/>
                    <measurement group_id="O2" value="-4.8" spread="0.3"/>
                    <measurement group_id="O3" value="-4.7" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="271"/>
                    <count group_id="O2" value="276"/>
                    <count group_id="O3" value="269"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="0.5"/>
                    <measurement group_id="O2" value="-6.2" spread="0.4"/>
                    <measurement group_id="O3" value="-6.5" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" spread="0.5"/>
                    <measurement group_id="O2" value="-6.8" spread="0.4"/>
                    <measurement group_id="O3" value="-7.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="257"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="0.5"/>
                    <measurement group_id="O2" value="-7.3" spread="0.4"/>
                    <measurement group_id="O3" value="-7.8" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="257"/>
                    <count group_id="O3" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="0.5"/>
                    <measurement group_id="O2" value="-7.6" spread="0.5"/>
                    <measurement group_id="O3" value="-7.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="245"/>
                    <count group_id="O2" value="248"/>
                    <count group_id="O3" value="243"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="0.5"/>
                    <measurement group_id="O2" value="-9.0" spread="0.5"/>
                    <measurement group_id="O3" value="-8.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="239"/>
                    <count group_id="O3" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="0.5"/>
                    <measurement group_id="O2" value="-9.2" spread="0.5"/>
                    <measurement group_id="O3" value="-8.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician Global Assessment of Disease Activity Over Time</title>
        <description>A global assessment of the participant's arthritis assessed by the physician on a 100 mm visual analog scale (VAS) where 0 mm = No activity at all and 100 mm = Worst activity imaginable.</description>
        <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
        <population>All randomized participants with non-missing data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician Global Assessment of Disease Activity Over Time</title>
          <description>A global assessment of the participant's arthritis assessed by the physician on a 100 mm visual analog scale (VAS) where 0 mm = No activity at all and 100 mm = Worst activity imaginable.</description>
          <population>All randomized participants with non-missing data at each time point</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="278"/>
                    <count group_id="O2" value="278"/>
                    <count group_id="O3" value="277"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.8" spread="1.2"/>
                    <measurement group_id="O2" value="-23.1" spread="1.2"/>
                    <measurement group_id="O3" value="-22.8" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="271"/>
                    <count group_id="O2" value="277"/>
                    <count group_id="O3" value="269"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.0" spread="1.4"/>
                    <measurement group_id="O2" value="-29.7" spread="1.4"/>
                    <measurement group_id="O3" value="-30.4" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.8" spread="1.6"/>
                    <measurement group_id="O2" value="-32.7" spread="1.6"/>
                    <measurement group_id="O3" value="-33.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                    <count group_id="O2" value="257"/>
                    <count group_id="O3" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.3" spread="1.7"/>
                    <measurement group_id="O2" value="-34.9" spread="1.5"/>
                    <measurement group_id="O3" value="-36.2" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="250"/>
                    <count group_id="O2" value="257"/>
                    <count group_id="O3" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.6" spread="1.8"/>
                    <measurement group_id="O2" value="-35.7" spread="1.7"/>
                    <measurement group_id="O3" value="-35.8" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="241"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="241"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.1" spread="1.7"/>
                    <measurement group_id="O2" value="-42.8" spread="1.5"/>
                    <measurement group_id="O3" value="-39.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="239"/>
                    <count group_id="O3" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.4" spread="1.5"/>
                    <measurement group_id="O2" value="-43.8" spread="1.4"/>
                    <measurement group_id="O3" value="-41.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Assessment of Disease Activity Over Time</title>
        <description>A global assessment of the participant's arthritis, assessed by the participant on a 100 mm VAS where 0 mm = No arthritis activity at all and 100 mm = Worst arthritis activity imaginable.</description>
        <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
        <population>All randomized participants with non-missing data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Assessment of Disease Activity Over Time</title>
          <description>A global assessment of the participant's arthritis, assessed by the participant on a 100 mm VAS where 0 mm = No arthritis activity at all and 100 mm = Worst arthritis activity imaginable.</description>
          <population>All randomized participants with non-missing data at each time point</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="280"/>
                    <count group_id="O2" value="281"/>
                    <count group_id="O3" value="277"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.0" spread="1.5"/>
                    <measurement group_id="O2" value="-21.9" spread="1.6"/>
                    <measurement group_id="O3" value="-21.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="271"/>
                    <count group_id="O2" value="277"/>
                    <count group_id="O3" value="269"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.6" spread="1.6"/>
                    <measurement group_id="O2" value="-27.3" spread="1.6"/>
                    <measurement group_id="O3" value="-26.4" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="268"/>
                    <count group_id="O3" value="264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.6" spread="1.6"/>
                    <measurement group_id="O2" value="-29.9" spread="1.7"/>
                    <measurement group_id="O3" value="-28.0" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="257"/>
                    <count group_id="O3" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.7" spread="1.7"/>
                    <measurement group_id="O2" value="-30.9" spread="1.7"/>
                    <measurement group_id="O3" value="-29.3" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="258"/>
                    <count group_id="O3" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.0" spread="1.8"/>
                    <measurement group_id="O2" value="-32.3" spread="1.7"/>
                    <measurement group_id="O3" value="-29.6" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="248"/>
                    <count group_id="O3" value="241"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.0" spread="1.8"/>
                    <measurement group_id="O2" value="-36.4" spread="1.8"/>
                    <measurement group_id="O3" value="-32.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="238"/>
                    <count group_id="O3" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.9" spread="1.9"/>
                    <measurement group_id="O2" value="-38.8" spread="1.7"/>
                    <measurement group_id="O3" value="-33.3" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Assessment of Joint Pain Over Time</title>
        <description>A global assessment of the severity of the participant's joint pain, assessed by the participant on a 100 mm VAS where 0 mm = No pain at all and 100 mm = Worst pain imaginable.</description>
        <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
        <population>All randomized participants with non-missing data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Assessment of Joint Pain Over Time</title>
          <description>A global assessment of the severity of the participant's joint pain, assessed by the participant on a 100 mm VAS where 0 mm = No pain at all and 100 mm = Worst pain imaginable.</description>
          <population>All randomized participants with non-missing data at each time point</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="280"/>
                    <count group_id="O2" value="281"/>
                    <count group_id="O3" value="277"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="1.4"/>
                    <measurement group_id="O2" value="-18.4" spread="1.5"/>
                    <measurement group_id="O3" value="-18.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="271"/>
                    <count group_id="O2" value="277"/>
                    <count group_id="O3" value="269"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.5" spread="1.5"/>
                    <measurement group_id="O2" value="-23.5" spread="1.5"/>
                    <measurement group_id="O3" value="-24.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="268"/>
                    <count group_id="O3" value="264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.0" spread="1.6"/>
                    <measurement group_id="O2" value="-24.1" spread="1.7"/>
                    <measurement group_id="O3" value="-24.9" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="257"/>
                    <count group_id="O3" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.9" spread="1.7"/>
                    <measurement group_id="O2" value="-25.9" spread="1.7"/>
                    <measurement group_id="O3" value="-25.6" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="258"/>
                    <count group_id="O3" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.6" spread="1.7"/>
                    <measurement group_id="O2" value="-26.4" spread="1.7"/>
                    <measurement group_id="O3" value="-26.9" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="248"/>
                    <count group_id="O3" value="241"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.9" spread="1.7"/>
                    <measurement group_id="O2" value="-31.5" spread="1.7"/>
                    <measurement group_id="O3" value="-28.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="238"/>
                    <count group_id="O3" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.2" spread="1.8"/>
                    <measurement group_id="O2" value="-32.5" spread="1.7"/>
                    <measurement group_id="O3" value="-31.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) Over Time</title>
        <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.</description>
        <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
        <population>All randomized participants with non-missing data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) Over Time</title>
          <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.</description>
          <population>All randomized participants with non-missing data at each time point</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="280"/>
                    <count group_id="O2" value="281"/>
                    <count group_id="O3" value="277"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.188" spread="0.024"/>
                    <measurement group_id="O2" value="-0.266" spread="0.024"/>
                    <measurement group_id="O3" value="-0.306" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="271"/>
                    <count group_id="O2" value="276"/>
                    <count group_id="O3" value="269"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.277" spread="0.029"/>
                    <measurement group_id="O2" value="-0.365" spread="0.031"/>
                    <measurement group_id="O3" value="-0.403" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="268"/>
                    <count group_id="O3" value="264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.310" spread="0.030"/>
                    <measurement group_id="O2" value="-0.404" spread="0.029"/>
                    <measurement group_id="O3" value="-0.450" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="257"/>
                    <count group_id="O3" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.378" spread="0.036"/>
                    <measurement group_id="O2" value="-0.454" spread="0.033"/>
                    <measurement group_id="O3" value="-0.483" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="258"/>
                    <count group_id="O3" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.412" spread="0.036"/>
                    <measurement group_id="O2" value="-0.444" spread="0.035"/>
                    <measurement group_id="O3" value="-0.468" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="248"/>
                    <count group_id="O3" value="241"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.452" spread="0.038"/>
                    <measurement group_id="O2" value="-0.496" spread="0.039"/>
                    <measurement group_id="O3" value="-0.548" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="238"/>
                    <count group_id="O3" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.526" spread="0.041"/>
                    <measurement group_id="O2" value="-0.557" spread="0.038"/>
                    <measurement group_id="O3" value="-0.554" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-reactive Protein Concentration Over Time</title>
        <description>C-reactive protein (CRP) is a specific measure of inflammatory activity.</description>
        <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
        <population>All randomized participants with non-missing data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-reactive Protein Concentration Over Time</title>
          <description>C-reactive protein (CRP) is a specific measure of inflammatory activity.</description>
          <population>All randomized participants with non-missing data at each time point</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="265"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.93" spread="0.93"/>
                    <measurement group_id="O2" value="-5.91" spread="1.01"/>
                    <measurement group_id="O3" value="-5.49" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="270"/>
                    <count group_id="O2" value="265"/>
                    <count group_id="O3" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.31" spread="0.90"/>
                    <measurement group_id="O2" value="-7.51" spread="0.94"/>
                    <measurement group_id="O3" value="-5.19" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="262"/>
                    <count group_id="O2" value="255"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.36" spread="0.84"/>
                    <measurement group_id="O2" value="-7.38" spread="0.99"/>
                    <measurement group_id="O3" value="-5.71" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="241"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.81" spread="0.82"/>
                    <measurement group_id="O2" value="-7.40" spread="1.03"/>
                    <measurement group_id="O3" value="-5.59" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="249"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.60" spread="0.91"/>
                    <measurement group_id="O2" value="-6.91" spread="1.15"/>
                    <measurement group_id="O3" value="-5.82" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="236"/>
                    <count group_id="O2" value="234"/>
                    <count group_id="O3" value="230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.16" spread="0.96"/>
                    <measurement group_id="O2" value="-7.36" spread="1.13"/>
                    <measurement group_id="O3" value="-5.82" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="223"/>
                    <count group_id="O2" value="226"/>
                    <count group_id="O3" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.88" spread="1.03"/>
                    <measurement group_id="O2" value="-7.45" spread="1.10"/>
                    <measurement group_id="O3" value="-5.81" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a American Minimal Disease Activity (MDA) Response Over Time</title>
        <description>Minimal Disease Activity (MDA) is a measure of low disease activity specific for psoriatic arthritis (PsA) that incorporates measures of joint and entheseal inflammation, skin disease, patient reported outcomes and functional disability to assess disease activity. Participants were classified as achieving MDA if they fulfilled 5 of the following 7 outcome measures:
Tender joint count (0-68) ≤ 1
Swollen joint count (0-66) ≤ 1
Body surface area (BSA) involvement with psoriasis (0% to 100%) ≤ 3%
Patient global assessment of joint pain VAS (0-100) ≤ 15
Patient global assessment of disease activity VAS (0-100) ≤ 20
HAQ-DI (0-3) ≤ 0.5
Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index (18 sites assessed for enthesitis with an overall score of 0 - 16) ≤ 1</description>
        <time_frame>Weeks 4, 8, 12, 24, 36, and 48</time_frame>
        <population>All randomized participants with non-missing data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a American Minimal Disease Activity (MDA) Response Over Time</title>
          <description>Minimal Disease Activity (MDA) is a measure of low disease activity specific for psoriatic arthritis (PsA) that incorporates measures of joint and entheseal inflammation, skin disease, patient reported outcomes and functional disability to assess disease activity. Participants were classified as achieving MDA if they fulfilled 5 of the following 7 outcome measures:
Tender joint count (0-68) ≤ 1
Swollen joint count (0-66) ≤ 1
Body surface area (BSA) involvement with psoriasis (0% to 100%) ≤ 3%
Patient global assessment of joint pain VAS (0-100) ≤ 15
Patient global assessment of disease activity VAS (0-100) ≤ 20
HAQ-DI (0-3) ≤ 0.5
Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index (18 sites assessed for enthesitis with an overall score of 0 - 16) ≤ 1</description>
          <population>All randomized participants with non-missing data at each time point</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                    <count group_id="O2" value="280"/>
                    <count group_id="O3" value="278"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="11.1"/>
                    <measurement group_id="O3" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="271"/>
                    <count group_id="O2" value="276"/>
                    <count group_id="O3" value="270"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="9.4"/>
                    <measurement group_id="O3" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                    <count group_id="O2" value="268"/>
                    <count group_id="O3" value="265"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="29.9"/>
                    <measurement group_id="O3" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="258"/>
                    <count group_id="O3" value="258"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7"/>
                    <measurement group_id="O2" value="39.5"/>
                    <measurement group_id="O3" value="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="248"/>
                    <count group_id="O3" value="242"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3"/>
                    <measurement group_id="O2" value="43.5"/>
                    <measurement group_id="O3" value="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="238"/>
                    <count group_id="O3" value="233"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8"/>
                    <measurement group_id="O2" value="51.3"/>
                    <measurement group_id="O3" value="53.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) Over Time</title>
        <description>PASDAS is a measure of disease activity derived from the following variables:
Physician and patient global assessment of disease activity (assessed on a 0-100 VAS)
68 tender joint count
66 swollen joint count
Short Form-36 Questionnaire (SF-36) physical component summary (general health status on a scale from 0-100)
Tender dactylitis count (each digit assessed for tender dactylitis; total score 0-20)
Leeds enthesitis index (enthesitis assessed at 6 sites; total score of 0-6)
CRP level (mg/L)
The composite score is a weighted index where higher scores indicate more severe disease.</description>
        <time_frame>Baseline and weeks 12, 24, 36, and 48</time_frame>
        <population>All randomized participants with non-missing data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) Over Time</title>
          <description>PASDAS is a measure of disease activity derived from the following variables:
Physician and patient global assessment of disease activity (assessed on a 0-100 VAS)
68 tender joint count
66 swollen joint count
Short Form-36 Questionnaire (SF-36) physical component summary (general health status on a scale from 0-100)
Tender dactylitis count (each digit assessed for tender dactylitis; total score 0-20)
Leeds enthesitis index (enthesitis assessed at 6 sites; total score of 0-6)
CRP level (mg/L)
The composite score is a weighted index where higher scores indicate more severe disease.</description>
          <population>All randomized participants with non-missing data at each time point</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="261"/>
                    <count group_id="O2" value="263"/>
                    <count group_id="O3" value="261"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="0.08"/>
                    <measurement group_id="O2" value="-2.32" spread="0.09"/>
                    <measurement group_id="O3" value="-2.37" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="250"/>
                    <count group_id="O3" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.98" spread="0.10"/>
                    <measurement group_id="O2" value="-2.64" spread="0.10"/>
                    <measurement group_id="O3" value="-2.63" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="238"/>
                    <count group_id="O3" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.46" spread="0.10"/>
                    <measurement group_id="O2" value="-3.10" spread="0.10"/>
                    <measurement group_id="O3" value="-2.95" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="226"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.70" spread="0.10"/>
                    <measurement group_id="O2" value="-3.23" spread="0.09"/>
                    <measurement group_id="O3" value="-3.10" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of change from baseline in PASDAS at week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-0.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of change from baseline in PASDAS at week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt;30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-0.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.92</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Disease Activity Index (CDAI) Over Time</title>
        <description>The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the following items:
28 tender joint count,
28 swollen joint count,
Patient's Global Assessment of Disease Activity measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest;
Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest.
The CDAI score ranges from 0-76 where lower scores indicate less disease activity.</description>
        <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
        <population>All randomized participants with non-missing data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Disease Activity Index (CDAI) Over Time</title>
          <description>The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the following items:
28 tender joint count,
28 swollen joint count,
Patient's Global Assessment of Disease Activity measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest;
Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest.
The CDAI score ranges from 0-76 where lower scores indicate less disease activity.</description>
          <population>All randomized participants with non-missing data at each time point</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="276"/>
                    <count group_id="O2" value="277"/>
                    <count group_id="O3" value="276"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.38" spread="0.62"/>
                    <measurement group_id="O2" value="-10.59" spread="0.61"/>
                    <measurement group_id="O3" value="-10.68" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="270"/>
                    <count group_id="O2" value="276"/>
                    <count group_id="O3" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.56" spread="0.73"/>
                    <measurement group_id="O2" value="-14.13" spread="0.66"/>
                    <measurement group_id="O3" value="-14.56" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="265"/>
                    <count group_id="O2" value="266"/>
                    <count group_id="O3" value="263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.93" spread="0.74"/>
                    <measurement group_id="O2" value="-15.61" spread="0.75"/>
                    <measurement group_id="O3" value="-16.12" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="250"/>
                    <count group_id="O2" value="256"/>
                    <count group_id="O3" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.20" spread="0.80"/>
                    <measurement group_id="O2" value="-16.49" spread="0.70"/>
                    <measurement group_id="O3" value="-17.37" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="257"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.74" spread="0.85"/>
                    <measurement group_id="O2" value="-17.12" spread="0.78"/>
                    <measurement group_id="O3" value="-16.43" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="240"/>
                    <count group_id="O2" value="246"/>
                    <count group_id="O3" value="239"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.90" spread="0.76"/>
                    <measurement group_id="O2" value="-19.79" spread="0.76"/>
                    <measurement group_id="O3" value="-18.86" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="238"/>
                    <count group_id="O3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.16" spread="0.80"/>
                    <measurement group_id="O2" value="-20.78" spread="0.75"/>
                    <measurement group_id="O3" value="-19.35" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of change from baseline in CDAI at week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.59</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-0.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.93</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of change from baseline in CDAI at week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.26</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-1.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.63</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Simplified Disease Activity Index (SDAI) Over Time</title>
        <description>The Simplified Disease Activity Index (SDAI) is a composite index that is calculated as the sum of the following items:
28 tender joint count,
28 swollen joint count,
Patient's Global Assessment of Disease Activity measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest;
Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest.
CRP
The SDAI score ranges from 0 to 86 with higher scores representing worse disease.</description>
        <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
        <population>All randomized participants with non-missing data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Simplified Disease Activity Index (SDAI) Over Time</title>
          <description>The Simplified Disease Activity Index (SDAI) is a composite index that is calculated as the sum of the following items:
28 tender joint count,
28 swollen joint count,
Patient's Global Assessment of Disease Activity measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest;
Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest.
CRP
The SDAI score ranges from 0 to 86 with higher scores representing worse disease.</description>
          <population>All randomized participants with non-missing data at each time point</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="273"/>
                    <count group_id="O3" value="273"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.38" spread="0.62"/>
                    <measurement group_id="O2" value="-11.12" spread="0.62"/>
                    <measurement group_id="O3" value="-11.18" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="270"/>
                    <count group_id="O2" value="272"/>
                    <count group_id="O3" value="267"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.77" spread="0.72"/>
                    <measurement group_id="O2" value="-14.92" spread="0.69"/>
                    <measurement group_id="O3" value="-15.14" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                    <count group_id="O2" value="264"/>
                    <count group_id="O3" value="263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.32" spread="0.75"/>
                    <measurement group_id="O2" value="-16.44" spread="0.77"/>
                    <measurement group_id="O3" value="-16.67" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="253"/>
                    <count group_id="O3" value="246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.55" spread="0.81"/>
                    <measurement group_id="O2" value="-17.25" spread="0.72"/>
                    <measurement group_id="O3" value="-17.79" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="253"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.96" spread="0.86"/>
                    <measurement group_id="O2" value="-17.75" spread="0.81"/>
                    <measurement group_id="O3" value="-17.01" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="242"/>
                    <count group_id="O3" value="235"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.27" spread="0.77"/>
                    <measurement group_id="O2" value="-20.50" spread="0.78"/>
                    <measurement group_id="O3" value="-19.46" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="234"/>
                    <count group_id="O3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.65" spread="0.81"/>
                    <measurement group_id="O2" value="-21.61" spread="0.77"/>
                    <measurement group_id="O3" value="-19.94" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of change from baseline in SDAI at week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.41</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-0.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.35</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of change from baseline in SDAI at week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.15</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-1.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.09</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Disease Activity Score 28 (DAS28) Over Time</title>
        <description>The DAS28 measures the severity of disease at a specific time and is derived from the following variables:
28 tender joint count
28 swollen joint count
C-reactive protein (CRP)
Patient's global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest.
DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.</description>
        <time_frame>Baseline and weeks 4, 8, 12, 16, 24, 36, and 48</time_frame>
        <population>All randomized participants with non-missing data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Disease Activity Score 28 (DAS28) Over Time</title>
          <description>The DAS28 measures the severity of disease at a specific time and is derived from the following variables:
28 tender joint count
28 swollen joint count
C-reactive protein (CRP)
Patient's global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest.
DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.</description>
          <population>All randomized participants with non-missing data at each time point</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="278"/>
                    <count group_id="O2" value="275"/>
                    <count group_id="O3" value="273"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="0.05"/>
                    <measurement group_id="O2" value="-1.18" spread="0.06"/>
                    <measurement group_id="O3" value="-1.21" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="270"/>
                    <count group_id="O2" value="272"/>
                    <count group_id="O3" value="267"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" spread="0.06"/>
                    <measurement group_id="O2" value="-1.64" spread="0.07"/>
                    <measurement group_id="O3" value="-1.61" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                    <count group_id="O2" value="265"/>
                    <count group_id="O3" value="263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="0.06"/>
                    <measurement group_id="O2" value="-1.78" spread="0.08"/>
                    <measurement group_id="O3" value="-1.80" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="250"/>
                    <count group_id="O2" value="253"/>
                    <count group_id="O3" value="246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="0.07"/>
                    <measurement group_id="O2" value="-1.90" spread="0.08"/>
                    <measurement group_id="O3" value="-1.92" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                    <count group_id="O2" value="253"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="0.08"/>
                    <measurement group_id="O2" value="-1.97" spread="0.08"/>
                    <measurement group_id="O3" value="-1.86" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="242"/>
                    <count group_id="O2" value="244"/>
                    <count group_id="O3" value="236"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.88" spread="0.07"/>
                    <measurement group_id="O2" value="-2.25" spread="0.08"/>
                    <measurement group_id="O3" value="-2.20" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="234"/>
                    <count group_id="O3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" spread="0.07"/>
                    <measurement group_id="O2" value="-2.38" spread="0.08"/>
                    <measurement group_id="O3" value="-2.23" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of change from baseline in DAS28 at week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt;30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-0.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of change from baseline in DAS28 at week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt;30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24</title>
        <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring in 8 functional areas: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>All randomized participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24</title>
          <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring in 8 functional areas: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement in functional ability.</description>
          <population>All randomized participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="258"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.412" spread="0.036"/>
                    <measurement group_id="O2" value="-0.444" spread="0.035"/>
                    <measurement group_id="O3" value="-0.468" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.34</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt;30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.67</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Medical Outcomes Health Survey Short Form 36 Items Version 2 (SF-36 v2) at Week 24</title>
        <description>The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains. Two summary component scores are calculated: mental component summary score (MCS) and physical component summary score (PCS). The MCS consists of social functioning, vitality, mental health, and role-emotional scales and the PCS consists of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>All randomized participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medical Outcomes Health Survey Short Form 36 Items Version 2 (SF-36 v2) at Week 24</title>
          <description>The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains. Two summary component scores are calculated: mental component summary score (MCS) and physical component summary score (PCS). The MCS consists of social functioning, vitality, mental health, and role-emotional scales and the PCS consists of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning.</description>
          <population>All randomized participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.952" spread="0.550"/>
                    <measurement group_id="O2" value="7.808" spread="0.546"/>
                    <measurement group_id="O3" value="8.011" spread="0.598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.259" spread="0.589"/>
                    <measurement group_id="O2" value="2.835" spread="0.624"/>
                    <measurement group_id="O3" value="3.321" spread="0.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of change from baseline in Physical Component Summary at week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt;30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>1.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>3.51</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of change from baseline in Physical Component Summary at week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.033</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>1.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>3.28</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of change from baseline in Mental Component Summary at week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.97</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.84</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.69</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of change from baseline in Mental Component Summary at week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.56</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-0.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.85</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.16</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) at Week 24</title>
        <description>The modified NAPSI scale is a grading system for nail psoriasis that incorporates the following 7 clinical features:
pitting (scores 0-3, depending on the number of pits)
nail plate crumbling (scores 0-3, depending on the % of nail involvement)
onycholysis and oil drop dyschromia (scores 0-3, depending on the % of nail involvement)
leukonychia (0 = absent, 1 = present)
red spots in lunula (0 = absent, 1 = present)
nail bed hyperkeratosis (0 = absent, 1 = present)
splinter hemorrhages (0 = absent, 1 = present)
In participants with fingernails involved with psoriasis, each fingernail was scored at baseline to determine the worst fingernail (ie, the fingernail with the highest mNAPSI score). This fingernail was followed for the remainder of the study.
mNAPSI scores range from 0-13 where higher scores represent worse nail disease.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Randomized participants with non-zero mNAPSI score at baseline and available data at week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) at Week 24</title>
          <description>The modified NAPSI scale is a grading system for nail psoriasis that incorporates the following 7 clinical features:
pitting (scores 0-3, depending on the number of pits)
nail plate crumbling (scores 0-3, depending on the % of nail involvement)
onycholysis and oil drop dyschromia (scores 0-3, depending on the % of nail involvement)
leukonychia (0 = absent, 1 = present)
red spots in lunula (0 = absent, 1 = present)
nail bed hyperkeratosis (0 = absent, 1 = present)
splinter hemorrhages (0 = absent, 1 = present)
In participants with fingernails involved with psoriasis, each fingernail was scored at baseline to determine the worst fingernail (ie, the fingernail with the highest mNAPSI score). This fingernail was followed for the remainder of the study.
mNAPSI scores range from 0-13 where higher scores represent worse nail disease.</description>
          <population>Randomized participants with non-zero mNAPSI score at baseline and available data at week 24</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.2"/>
                    <measurement group_id="O2" value="-1.5" spread="0.2"/>
                    <measurement group_id="O3" value="-1.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.020</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt;30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.10</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clear mNAPSI at Week 24</title>
        <description>The modified NAPSI scale is a grading system for nail psoriasis that incorporates the following 7 clinical features:
pitting (scores 0-3, depending on the number of pits)
nail plate crumbling (scores 0-3, depending on the % of nail involvement)
onycholysis and oil drop dyschromia (scores 0-3, depending on the % of nail involvement)
leukonychia (0 = absent, 1 = present)
red spots in lunula (0 = absent, 1 = present)
nail bed hyperkeratosis (0 = absent, 1 = present)
splinter hemorrhages (0 = absent, 1 = present)
In participants with fingernails involved with psoriasis, each fingernail was scored at baseline to determine the worst fingernail (ie, the fingernail with the highest mNAPSI score). This fingernail was followed for the remainder of the study.
mNAPSI scores range from 0-13 where higher scores represent worse nail disease. Clear mNAPSI is defined as a score = 0.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Randomized participants with non-zero mNAPSI score at baseline and available data at week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clear mNAPSI at Week 24</title>
          <description>The modified NAPSI scale is a grading system for nail psoriasis that incorporates the following 7 clinical features:
pitting (scores 0-3, depending on the number of pits)
nail plate crumbling (scores 0-3, depending on the % of nail involvement)
onycholysis and oil drop dyschromia (scores 0-3, depending on the % of nail involvement)
leukonychia (0 = absent, 1 = present)
red spots in lunula (0 = absent, 1 = present)
nail bed hyperkeratosis (0 = absent, 1 = present)
splinter hemorrhages (0 = absent, 1 = present)
In participants with fingernails involved with psoriasis, each fingernail was scored at baseline to determine the worst fingernail (ie, the fingernail with the highest mNAPSI score). This fingernail was followed for the remainder of the study.
mNAPSI scores range from 0-13 where higher scores represent worse nail disease. Clear mNAPSI is defined as a score = 0.</description>
          <population>Randomized participants with non-zero mNAPSI score at baseline and available data at week 24</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Leeds Dactylitis Index (LDI) at Week 24</title>
        <description>The Leeds dactylitis index quantitatively measures dactylitis using the circumference of involved digits and control digits and tenderness of involved digits. Digits affected by dactylitis are defined as those with a 10% difference in the ratio of circumference of the affected digit to the contralateral digit. The control digit is either the contralateral digit (digit on opposite hand or foot), or if the contralateral digit is also affected, values from a standard reference table. Tenderness of affected digits is assessed on a scale from 0 [none] to 3 [worst]. The ratio of circumference between an affected digit and the control digit is multiplied by the tenderness score for the affected digit. The results from each involved digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Randomized participants with non-zero LDI score at baseline and available data at week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Leeds Dactylitis Index (LDI) at Week 24</title>
          <description>The Leeds dactylitis index quantitatively measures dactylitis using the circumference of involved digits and control digits and tenderness of involved digits. Digits affected by dactylitis are defined as those with a 10% difference in the ratio of circumference of the affected digit to the contralateral digit. The control digit is either the contralateral digit (digit on opposite hand or foot), or if the contralateral digit is also affected, values from a standard reference table. Tenderness of affected digits is assessed on a scale from 0 [none] to 3 [worst]. The ratio of circumference between an affected digit and the control digit is multiplied by the tenderness score for the affected digit. The results from each involved digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis.</description>
          <population>Randomized participants with non-zero LDI score at baseline and available data at week 24</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-128.80" spread="26.76"/>
                    <measurement group_id="O2" value="-119.09" spread="20.66"/>
                    <measurement group_id="O3" value="-110.15" spread="22.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.68</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt;30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>13.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>33.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.52</ci_lower_limit>
            <ci_upper_limit>79.36</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.85</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>6.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>33.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.75</ci_lower_limit>
            <ci_upper_limit>71.42</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clear LDI at Week 24</title>
        <description>The Leeds dactylitis index quantitatively measures dactylitis using the circumference of involved digits and control digits and tenderness of involved digits. Digits affected by dactylitis are defined as those with a 10% difference in the ratio of circumference of the affected digit to the contralateral digit. The control digit is either the contralateral digit (digit on opposite hand or foot), or if the contralateral digit is also affected, values from a standard reference table. Tenderness of affected digits is assessed on a scale from 0 [none] to 3 [worst]. The ratio of circumference between an affected digit and the control digit is multiplied by the tenderness score for the affected digit. The results from each involved digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis.
Clear LDI is defined as a score = 0.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Randomized participants with non-zero LDI score at baseline and available data at week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clear LDI at Week 24</title>
          <description>The Leeds dactylitis index quantitatively measures dactylitis using the circumference of involved digits and control digits and tenderness of involved digits. Digits affected by dactylitis are defined as those with a 10% difference in the ratio of circumference of the affected digit to the contralateral digit. The control digit is either the contralateral digit (digit on opposite hand or foot), or if the contralateral digit is also affected, values from a standard reference table. Tenderness of affected digits is assessed on a scale from 0 [none] to 3 [worst]. The ratio of circumference between an affected digit and the control digit is multiplied by the tenderness score for the affected digit. The results from each involved digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis.
Clear LDI is defined as a score = 0.</description>
          <population>Randomized participants with non-zero LDI score at baseline and available data at week 24</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2"/>
                    <measurement group_id="O2" value="76.4"/>
                    <measurement group_id="O3" value="79.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.057</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test with baseline body mass index (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD treatment as stratification factors</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>12.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>26.2</ci_upper_limit>
            <estimate_desc>The risk difference was estimated using the Mantel-Haenszel estimate of common risk difference using the stratification factors described above.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test with baseline body mass index (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD treatment as stratification factors</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>10.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>24.4</ci_upper_limit>
            <estimate_desc>The risk difference was estimated using the Mantel-Haenszel estimate of common risk difference using the stratification factors described above.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index at Week 24</title>
        <description>The SPARCC enthesitis index assesses enthesitis at 18 sites for palpitation with a resultant total score of 0 to 16 (for scoring purposes, the inferior patella and tibial tuberosity are considered 1 site because of their anatomical proximity). Tenderness at each site is quantified on a dichotomous basis (0 = non-tender, 1 = tender). Entheses assessed are medial epicondyle (left and right), lateral epicondyle (left and right), supraspinatus insertion into greater tuberosity of humerus (left and right), greater trochanter (left and right), quadriceps insertion into superior border of patella (left and right), patellar ligament insertion into inferior pole of patella or tibial tubercle (left and right), Achilles tendon insertion into calcaneum (left and right), plantar fascia insertion into calcaneum (left and right). A higher count represents greater enthesitis burden.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Randomized participants with non-zero SPARCC enthesitis index score at baseline and available data at week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index at Week 24</title>
          <description>The SPARCC enthesitis index assesses enthesitis at 18 sites for palpitation with a resultant total score of 0 to 16 (for scoring purposes, the inferior patella and tibial tuberosity are considered 1 site because of their anatomical proximity). Tenderness at each site is quantified on a dichotomous basis (0 = non-tender, 1 = tender). Entheses assessed are medial epicondyle (left and right), lateral epicondyle (left and right), supraspinatus insertion into greater tuberosity of humerus (left and right), greater trochanter (left and right), quadriceps insertion into superior border of patella (left and right), patellar ligament insertion into inferior pole of patella or tibial tubercle (left and right), Achilles tendon insertion into calcaneum (left and right), plantar fascia insertion into calcaneum (left and right). A higher count represents greater enthesitis burden.</description>
          <population>Randomized participants with non-zero SPARCC enthesitis index score at baseline and available data at week 24</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="0.3"/>
                    <measurement group_id="O2" value="-3.0" spread="0.3"/>
                    <measurement group_id="O3" value="-2.9" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.70</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt;30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>0.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.66</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.93</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clear SPARCC Enthesitis Index Score at Week 24</title>
        <description>The SPARCC enthesitis index assesses enthesitis at 18 sites for palpitation with a resultant total score of 0 to 16 (for scoring purposes, the inferior patella and tibial tuberosity are considered 1 site because of their anatomical proximity). Tenderness at each site is quantified on a dichotomous basis (0 = non-tender, 1 = tender). Entheses assessed are medial epicondyle (left and right), lateral epicondyle (left and right), supraspinatus insertion into greater tuberosity of humerus (left and right), greater trochanter (left and right), quadriceps insertion into superior border of patella (left and right), patellar ligament insertion into inferior pole of patella or tibial tubercle (left and right), Achilles tendon insertion into calcaneum (left and right), plantar fascia insertion into calcaneum (left and right). A higher count represents greater enthesitis burden.
Clear SPARCC enthesitis is defined as a score = 0.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Randomized participants with non-zero SPARCC enthesitis index score at baseline and available data at week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clear SPARCC Enthesitis Index Score at Week 24</title>
          <description>The SPARCC enthesitis index assesses enthesitis at 18 sites for palpitation with a resultant total score of 0 to 16 (for scoring purposes, the inferior patella and tibial tuberosity are considered 1 site because of their anatomical proximity). Tenderness at each site is quantified on a dichotomous basis (0 = non-tender, 1 = tender). Entheses assessed are medial epicondyle (left and right), lateral epicondyle (left and right), supraspinatus insertion into greater tuberosity of humerus (left and right), greater trochanter (left and right), quadriceps insertion into superior border of patella (left and right), patellar ligament insertion into inferior pole of patella or tibial tubercle (left and right), Achilles tendon insertion into calcaneum (left and right), plantar fascia insertion into calcaneum (left and right). A higher count represents greater enthesitis burden.
Clear SPARCC enthesitis is defined as a score = 0.</description>
          <population>Randomized participants with non-zero SPARCC enthesitis index score at baseline and available data at week 24</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1"/>
                    <measurement group_id="O2" value="52.6"/>
                    <measurement group_id="O3" value="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.55</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test with baseline body mass index (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD treatment as stratification factors</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>13.7</ci_upper_limit>
            <estimate_desc>The risk difference was estimated using the Mantel-Haenszel estimate of common risk difference using the stratification factors described above.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test with baseline body mass index (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD treatment as stratification factors</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>8.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>19.4</ci_upper_limit>
            <estimate_desc>The risk difference was estimated using the Mantel-Haenszel estimate of common risk difference using the stratification factors described above.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Improvement From Baseline in the Percentage of Body Surface Area (BSA) Involved in Psoriasis at Week 24</title>
        <description>The physician's assessment of the percentage of the participant's total body surface area involved with psoriasis.
Percent improvement from baseline = (Baseline Value - Post-baseline Value) / Baseline * 100</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Randomized participants with ≥ 3% body surface area (BSA) psoriasis involvement at baseline and available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Improvement From Baseline in the Percentage of Body Surface Area (BSA) Involved in Psoriasis at Week 24</title>
          <description>The physician's assessment of the percentage of the participant's total body surface area involved with psoriasis.
Percent improvement from baseline = (Baseline Value - Post-baseline Value) / Baseline * 100</description>
          <population>Randomized participants with ≥ 3% body surface area (BSA) psoriasis involvement at baseline and available data.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.12" spread="2.76"/>
                    <measurement group_id="O2" value="69.80" spread="2.73"/>
                    <measurement group_id="O3" value="75.53" spread="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.031</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt;30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>9.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>17.87</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.49</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>3.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.49</ci_lower_limit>
            <ci_upper_limit>11.54</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Improvement From Baseline in the Percentage of Body Surface Area (BSA) Involved in Psoriasis by Baseline BSA Involvement Subgroups</title>
        <description>The physician's assessment of the percentage of the participant's total body surface area involved with psoriasis.
Percent improvement from baseline = (Baseline Value - Post-baseline Value) / Baseline * 100</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Randomized participants with available BSA data</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Improvement From Baseline in the Percentage of Body Surface Area (BSA) Involved in Psoriasis by Baseline BSA Involvement Subgroups</title>
          <description>The physician's assessment of the percentage of the participant's total body surface area involved with psoriasis.
Percent improvement from baseline = (Baseline Value - Post-baseline Value) / Baseline * 100</description>
          <population>Randomized participants with available BSA data</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 3% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.49" spread="46.71"/>
                    <measurement group_id="O2" value="-92.18" spread="108.54"/>
                    <measurement group_id="O3" value="17.66" spread="51.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3% to &lt; 10% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.61" spread="4.18"/>
                    <measurement group_id="O2" value="64.42" spread="4.43"/>
                    <measurement group_id="O3" value="68.76" spread="7.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 10% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.66" spread="3.66"/>
                    <measurement group_id="O2" value="74.23" spread="3.32"/>
                    <measurement group_id="O3" value="81.61" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of percent improvement from baseline in the percentage of BSA involved in psoriasis in the subgroup of participants with ≥ 10% BSA involvement at baseline.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>15.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.99</ci_lower_limit>
            <ci_upper_limit>24.90</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of percent improvement from baseline in the percentage of BSA involved in psoriasis in the subgroup of participants with ≥ 10% BSA involvement at baseline.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model adjusted for baseline BMI status (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD use.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>6.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.89</ci_lower_limit>
            <ci_upper_limit>15.83</ci_upper_limit>
            <estimate_desc>Methotrexate Monotherapy is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Physician Global Assessment (sPGA) at Week 24</title>
        <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
        <time_frame>Week 24</time_frame>
        <population>Randomized participants with ≥ 3% body surface area (BSA) psoriasis involvement at baseline and available sPGA data.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Static Physician Global Assessment (sPGA) at Week 24</title>
          <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
          <population>Randomized participants with ≥ 3% body surface area (BSA) psoriasis involvement at baseline and available sPGA data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 (clear)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 (almost clear)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (mild)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (moderate)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (marked)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (severe)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Physician Global Assessment (sPGA) at Week 24 by Baseline BSA Involvement Subgroups</title>
        <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
        <time_frame>Week 24</time_frame>
        <population>Randomized participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Static Physician Global Assessment (sPGA) at Week 24 by Baseline BSA Involvement Subgroups</title>
          <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
          <population>Randomized participants with available data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="258"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 3% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 (clear)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 (almost clear)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (mild)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (moderate)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (marked)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (severe)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3% to &lt; 10% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 (clear)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 (almost clear)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (mild)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (moderate)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (marked)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (severe)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 10% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 (clear)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 (almost clear)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (mild)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (moderate)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (marked)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (severe)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Static Physician Global Assessment (sPGA) Score at Week 24</title>
        <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
        <time_frame>Week 24</time_frame>
        <population>Randomized participants with ≥ 3% body surface area (BSA) psoriasis involvement at baseline and available sPGA data.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Static Physician Global Assessment (sPGA) Score at Week 24</title>
          <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
          <population>Randomized participants with ≥ 3% body surface area (BSA) psoriasis involvement at baseline and available sPGA data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.1"/>
                    <measurement group_id="O2" value="1.2" spread="0.1"/>
                    <measurement group_id="O3" value="0.9" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Static Physician Global Assessment (sPGA) Score at Week 24 by Baseline BSA Involvement Subgroups</title>
        <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
        <time_frame>Week 24</time_frame>
        <population>Randomized participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Static Physician Global Assessment (sPGA) Score at Week 24 by Baseline BSA Involvement Subgroups</title>
          <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
          <population>Randomized participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="258"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 3% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.1"/>
                    <measurement group_id="O2" value="1.1" spread="0.1"/>
                    <measurement group_id="O3" value="0.6" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3% to &lt; 10% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.1"/>
                    <measurement group_id="O2" value="1.3" spread="0.1"/>
                    <measurement group_id="O3" value="0.9" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 10% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.1"/>
                    <measurement group_id="O2" value="1.1" spread="0.1"/>
                    <measurement group_id="O3" value="0.9" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an sPGA Score of 0 (Clear) or 1 (Almost Clear) at Week 24</title>
        <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
        <time_frame>Week 24</time_frame>
        <population>Randomized participants with ≥ 3% body surface area (BSA) psoriasis involvement at baseline and available sPGA data.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an sPGA Score of 0 (Clear) or 1 (Almost Clear) at Week 24</title>
          <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
          <population>Randomized participants with ≥ 3% body surface area (BSA) psoriasis involvement at baseline and available sPGA data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3"/>
                    <measurement group_id="O2" value="72.3"/>
                    <measurement group_id="O3" value="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test with baseline body mass index (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD treatment as stratification factors</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>11.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.0</ci_lower_limit>
            <ci_upper_limit>20.8</ci_upper_limit>
            <estimate_desc>The risk difference was estimated using the Mantel-Haenszel estimate of common risk difference using the stratification factors described above.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.40</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test with baseline body mass index (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD treatment as stratification factors</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>14.0</ci_upper_limit>
            <estimate_desc>The risk difference was estimated using the Mantel-Haenszel estimate of common risk difference using the stratification factors described above.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an sPGA Score of 0 (Clear) or 1 (Almost Clear) at Week 24 by Baseline BSA Involvement Subgroups</title>
        <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
        <time_frame>Week 24</time_frame>
        <population>Randomized participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an sPGA Score of 0 (Clear) or 1 (Almost Clear) at Week 24 by Baseline BSA Involvement Subgroups</title>
          <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
          <population>Randomized participants with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="258"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 3% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0"/>
                    <measurement group_id="O2" value="71.7"/>
                    <measurement group_id="O3" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3% to &lt; 10% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.6"/>
                    <measurement group_id="O2" value="64.0"/>
                    <measurement group_id="O3" value="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 10% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.3"/>
                    <measurement group_id="O2" value="79.1"/>
                    <measurement group_id="O3" value="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of percentage of participants with an sPGA of 0 or 1 at Week 24 in participants with baseline BSA involvement with psoriasis ≥ 10%.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test with baseline body mass index (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD treatment as stratification factors</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>20.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.8</ci_lower_limit>
            <ci_upper_limit>33.3</ci_upper_limit>
            <estimate_desc>The risk difference was estimated using the Mantel-Haenszel estimate of common risk difference using the stratification factors described above.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of percentage of participants with an sPGA of 0 or 1 at Week 24 in participants with baseline BSA involvement with psoriasis ≥ 10%.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>P-value is unadjusted and considered descriptive.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test with baseline body mass index (≤ 30 kg/m² or &gt; 30 kg/m²) and prior non-biologic DMARD treatment as stratification factors</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>17.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.0</ci_lower_limit>
            <ci_upper_limit>30.2</ci_upper_limit>
            <estimate_desc>The risk difference was estimated using the Mantel-Haenszel estimate of common risk difference using the stratification factors described above.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least a 1 Grade Improvement in sPGA From Baseline at Week 24</title>
        <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Randomized participants with ≥ 3% body surface area (BSA) psoriasis involvement at baseline and available sPGA data.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 1 Grade Improvement in sPGA From Baseline at Week 24</title>
          <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
          <population>Randomized participants with ≥ 3% body surface area (BSA) psoriasis involvement at baseline and available sPGA data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9"/>
                    <measurement group_id="O2" value="28.9"/>
                    <measurement group_id="O3" value="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least a 1 Grade Improvement in sPGA From Baseline at Week 24 by Baseline BSA Involvement Subgroups</title>
        <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Randomized participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 1 Grade Improvement in sPGA From Baseline at Week 24 by Baseline BSA Involvement Subgroups</title>
          <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
          <population>Randomized participants with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="258"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 3% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0"/>
                    <measurement group_id="O2" value="44.6"/>
                    <measurement group_id="O3" value="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3% to &lt; 10% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="38.7"/>
                    <measurement group_id="O3" value="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 10% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9"/>
                    <measurement group_id="O2" value="20.9"/>
                    <measurement group_id="O3" value="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least a 2 Grade Improvement in sPGA From Baseline at Week 24</title>
        <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Randomized participants with ≥ 3% body surface area (BSA) psoriasis involvement at baseline and available sPGA data.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 2 Grade Improvement in sPGA From Baseline at Week 24</title>
          <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
          <population>Randomized participants with ≥ 3% body surface area (BSA) psoriasis involvement at baseline and available sPGA data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5"/>
                    <measurement group_id="O2" value="28.9"/>
                    <measurement group_id="O3" value="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least a 2 Grade Improvement in sPGA From Baseline at Week 24 by Baseline BSA Involvement Subgroups</title>
        <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Randomized participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Monotherapy</title>
            <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept Monotherapy</title>
            <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Etanercept + Methotrexate</title>
            <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 2 Grade Improvement in sPGA From Baseline at Week 24 by Baseline BSA Involvement Subgroups</title>
          <description>The static Physician Global Assessment of psoriasis (sPGA) evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale from 0 to 5:
0 = clear (no evidence of plaque elevation, erythema or scaling)
= almost clear (minimal plaque elevation, erythema or scaling)
= mild (mild plaque elevation or scaling, light red coloration)
= moderate (moderate plaque elevation, scaling, light red coloration)
= marked (marked plaque elevation, thick, non-tenacious scale predominates, bright red coloration)
= severe (severe plaque elevation, very thick tenacious scaling, dusky to deep red coloration).</description>
          <population>Randomized participants with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="258"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 3% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1"/>
                    <measurement group_id="O2" value="20.7"/>
                    <measurement group_id="O3" value="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3% to &lt; 10% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9"/>
                    <measurement group_id="O2" value="25.3"/>
                    <measurement group_id="O3" value="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 10% BSA involvement at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4"/>
                    <measurement group_id="O2" value="31.9"/>
                    <measurement group_id="O3" value="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48-week treatment period plus 30-day safety follow-up</time_frame>
      <desc>Two participants randomized to the Etanercept Monotherapy arm also received methotrexate in error, so are counted in the Etanercept + Methotrexate group for safety.
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Methotrexate Monotherapy</title>
          <description>Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Etanercept Monotherapy</title>
          <description>Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Etanercept + Methotrexate</title>
          <description>Participants received etanercept 50 mg a week by subcutaneous injection and oral methotrexate 20 mg a week for 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Supraventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary histoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Spinal fusion surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="214" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal sensation in eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Myopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pterygium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Mucous stools</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pancreatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Application site bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Early satiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Injection site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Injection site irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Injection site oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Puncture site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hypertransaminasaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Allergy to plants</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Adenoviral upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Chorioretinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Infected bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Laryngitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Lymph node abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Nail bed infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Nasal herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pharyngitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Post procedural pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dental restoration failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Foreign body in eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Lip injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Nail avulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Skin wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tooth avulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Traumatic haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Blood bilirubin abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Blood glucose abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Blood triglycerides abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Borrelia test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Endoscopy gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Precancerous cells present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Varicella virus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vitamin D decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hyper HDL cholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Impaired fasting glucose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vitamin B12 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Bone cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Chondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Coccydynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Enthesopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Myofascial pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Patellofemoral pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rheumatoid nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Elastofibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Osteoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hypogeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Meralgia paraesthetica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Seizure like phenomena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Attention deficit/hyperactivity disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Binge eating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Breast disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vulvovaginal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Nasal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Alopecia areata</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Nail discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Parapsoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Pruritus allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Seborrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Trichorrhexis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Menopause</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Female sterilisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
              <event>
                <sub_title>Vasodilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="284"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

